Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARTL

ARTL - Artelo Biosciences Inc Stock Price, Fair Value and News

1.53USD-0.01 (-0.65%)Delayed as of 01 Mar 2024, 10:15 am ET
Watchlist

Market Summary

USD1.53-0.01
Delayedas of 01 Mar 2024, 10:15 am
-0.65%

ARTL Stock Price

View Fullscreen

ARTL RSI Chart

ARTL Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

4.37

Price/Free Cashflow

-0.62

ARTL Price/Sales (Trailing)

ARTL Profitability

Return on Equity

-65.54%

Return on Assets

-61.65%

Free Cashflow Yield

-160.94%

ARTL Fundamentals

ARTL Revenue

Revenue (TTM)

1.1M

ARTL Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

-5.11%

Earnings Growth (Qtr)

-53.16%

Breaking Down ARTL Revenue

52 Week Range

1.362.98
(Low)(High)

Last 7 days

16.0%

Last 30 days

14.4%

Last 90 days

41.5%

Trailing 12 Months

-44.7%

How does ARTL drawdown profile look like?

ARTL Financial Health

Current Ratio

14.58

ARTL Investor Care

Shares Dilution (1Y)

11.67%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220000
20211.0M1.1M1.1M0
20201.3M1.2M978.0K1.0M
2019735.0K852.6K1.2M1.3M
2018331.9K491.8K585.1K645.0K
201775.4K98.7K121.9K220.1K
20160028.9K52.2K

Tracking the Latest Insider Buys and Sells of Artelo Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 12, 2022
gorgas gregory d.
bought
4,800
4.00
1,200
pres, ceo, cfo, treas & secr
Aug 11, 2022
gorgas gregory d.
bought
4,836
4.03
1,200
pres, ceo, cfo, treas & secr
Apr 16, 2021
gorgas gregory d.
bought
9,809
1.154
8,500
pres, ceo, cfo, treas & secr
May 15, 2020
gorgas gregory d.
bought
5,071
1.2076
4,200
pres, ceo, cfo, treas & secr
May 04, 2020
matsui connie
bought
50,000
1.2
41,667
-
May 04, 2020
gorgas gregory d.
bought
5,000
1.2
4,167
pres, ceo, cfo, treas & secr
Nov 04, 2019
gorgas gregory d.
bought
5,303
2.2098
2,400
pres, ceo, cfo, treas & secr
Nov 01, 2019
gorgas gregory d.
bought
5,701
2.2807
2,500
pres, ceo, cfo, treas & secr
Oct 31, 2019
gorgas gregory d.
bought
4,874
1.9499
2,500
pres, ceo, cfo, treas & secr
Oct 30, 2019
gorgas gregory d.
bought
5,186
1.9948
2,600
pres, ceo, cfo, treas & secr

1–10 of 13

Which funds bought or sold ARTL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-4.00
-
-%
Feb 14, 2024
Verition Fund Management LLC
unchanged
-
-230
1,089
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
-
6.00
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
-1.00
28.00
-%
Feb 13, 2024
FMR LLC
sold off
-100
-29.00
-
-%
Feb 13, 2024
NewEdge Advisors, LLC
new
-
1.00
1.00
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
added
124
3,595
6,724
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
unchanged
-
-1,386
27,533
-%
Feb 12, 2024
OSAIC HOLDINGS, INC.
new
-
9.00
9.00
-%
Feb 12, 2024
Alpine Global Management, LLC
reduced
-50.00
-1,002
563
-%

1–10 of 18

Are Funds Buying or Selling ARTL?

Are funds buying ARTL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARTL
No. of Funds

Unveiling Artelo Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 23, 2022
iroquois capital management, llc
0.24%
1e+05
SC 13G/A
Feb 09, 2022
parian global management lp
0%
0
SC 13G/A
Feb 04, 2022
hudson bay capital management lp
0%
0
SC 13G/A
Mar 01, 2021
parian global management lp
7.6%
1,199,738
SC 13G
Feb 16, 2021
cvi investments, inc.
4.9%
793,672
SC 13G/A
Feb 10, 2021
bigger capital fund l p
2.8%
450,000
SC 13G/A
Feb 08, 2021
hudson bay capital management lp
5.74%
920,000
SC 13G
Feb 05, 2021
kingsbrook partners lp
4.99%
8e+05
SC 13G/A
Jan 15, 2021
alpha capital anstalt
4.99%
784,008
SC 13G/A
Jan 13, 2021
empery asset management, lp
4.99%
920,000
SC 13G

Recent SEC filings of Artelo Biosciences Inc

View All Filings
Date Filed Form Type Document
Jan 08, 2024
4
Insider Trading

Peers (Alternatives to Artelo Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Artelo Biosciences Inc News

Latest updates
Defense World12 Feb 202410:21 am
Genetic Engineering & Biotechnology News22 months ago

Artelo Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q32022Q22022Q12022Q12021Q42021Q32021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue-100.0%-1.001.0054.00107160213226198195193304215266433354210167121236120
Operating Expenses-3.1%2,3942,4711,946-2,5522,2451,5172,2511,8681,4361,0289511,3711,336953941758----
  S&GA Expenses-7.0%1,3161,4151,482-1,2791,2116971,0741,0068411,54138943440328640358.00----
  R&D Expenses2.1%1,0781,056464-1,2731,034933951663595272259721667234184490----
Interest Expenses-5.00--------------------
Income Taxes----------------------
Net Income4.9%-2,330-2,449-1,965--2,548-2,245-1,517-2,249-1,865-1,435-1,027-951-1,370-1,306-845-344-424----
Net Income Margin2.0%-9.97*-10.17*-9.98*-9.57*-7.92*-7.65*-7.14*-7.46*-6.21*------------
Free Cashflow13.7%-1,696-1,966-2,053-2,667-1,926-1,055-1,055-1,742-945------------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-8.2%15,49916,87718,47820,42422,41524,40526,70428,25129,00412,63512,34013,4459,5394,3763,4944,1525,5486,4831,153484165
  Current Assets-8.0%13,42814,60216,38618,32220,30322,28224,58924,60925,35510,31710,30011,4057,5002,3371,4532,1113,5084,4431,152484165
    Cash Equivalents-53.9%2,6395,7196,9166,8887,13612,12210,35012,16214,0476,62910,05210,7067,3892,1421,2791,9833,3754,424286457-
  Net PPE-----------63*124*185*246*1.002.00598*721*857*414*481*
Liabilities51.2%9216098401,0215125679241,084718593570547524501-------
  Current Liabilities52.7%9216038259984805278751,0276595264245894865012684445851,0221,0191,176641
Shareholder's Equity-10.4%14,57816,26817,63819,40321,90323,83825,78027,16728,28612,04211,91612,8569,0543,8753,2253,7084,9635,4601342,937-
  Retained Earnings-7.0%-37,237-34,788-33,189-31,021-27,682-25,352-22,903-20,938-19,451-16,903-15,015-12,766-10,900-9,466-8,438-7,487-6,117-4,810-3,965-3,620-3,195
  Additional Paid-In Capital1.5%52,01151,25451,02950,67549,97049,32448,70548,12047,71828,92526,85925,55219,89113,27211,60911,17611,07110,2784,1082,9232,713
Accumulated Depreciation-----------2.002.001.001.001.001.00886*792*646*415*344*
Shares Outstanding10.7%3,1622,8562,8562,8562,8562,8402,8202,8202,8201,6351,5431,4811,007--------
Float------13,685-----39,891---2,970---12,812-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q42021Q32021Q32021Q22021Q22021Q12021Q12020Q42020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-11.0%-1,802-1,623-2,186-2,293-1,696-1,966-2,053-2,667-1,926--1,055---1,742-945-1,874-1,320-872-1,020-1,402-1,051
  Share Based Compensation-1.3%222225354608607619624934571502-609-51932370.0051.0055.0053.00105168
Cashflow From Investing-559.1%-1,8323992,1991,796-3,0803,985257-10,033-8,878---1,289--2,044544-1,055-1.00---
Cashflow From Financing-535--134--134-18,26118,262-890--6,0095,3206,5786,5791,7102832.00-13.97

ARTL Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
OPERATING EXPENSES    
General and administrative$ 1,029$ 1,316$ 3,118$ 4,213
Research and development1,5851,0783,5722,598
Total Operating Expenses2,6142,3946,6906,811
Loss from Operations(2,614)(2,394)(6,690)(6,811)
OTHER INCOME (EXPENSE)    
Interest income0002
Interest expense0(5)0(5)
Net change in fair value of trading marketable securities1656947470
Total other income1656447467
Provision for income taxes0000
NET LOSS(2,449)(2,330)(6,216)(6,744)
OTHER COMPREHENSIVE INCOME (LOSS)    
Unrealized loss on available-for-sale securities0(2)0(31)
Foreign currency translation adjustments2(210)55(339)
Total Other Comprehensive Income (Loss)2(212)55(370)
TOTAL COMPREHENSIVE LOSS$ (2,447)$ (2,542)$ (6,161)$ (7,114)
Basic and Diluted Loss per Common Share$ (0.83)$ (0.82)$ (2.15)$ (2.38)
Basic and Diluted Weighted Average Common Shares Outstanding2,9492,8492,8872,833

ARTL Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 2,639$ 6,888
Trading marketable securities10,2259,150
Available-for-sale securities (amortized cost of $0 and $1,502, respectively)01,495
Prepaid expenses and other current assets564789
Total Current Assets13,42818,322
Operating lease right-of-use assets2960
Intangible asset2,0392,039
Other assets33
TOTAL ASSETS15,49920,424
Current Liabilities  
Accounts payable and accrued liabilities840905
Due to related parties4953
Operating lease liabilities - current portion3240
Total Current Liabilities921998
Operating lease liabilities023
TOTAL LIABILITIES9211,021
STOCKHOLDERS' EQUITY  
Preferred Stock, par value $0.001, 416,667 shares authorized, 0 shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common Stock, par value $0.001, 50,000,000 shares authorized, as of September 30, 2023 and December 31, 2022 3,162,354 and 2,855,688 shares issued and outstanding as of September 30, 2023 and December 31, 202233
Additional paid-in capital52,01150,675
Accumulated deficit(37,237)(31,021)
Accumulated other comprehensive loss(199)(254)
TOTAL STOCKHOLDERS' EQUITY14,57819,403
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 15,499$ 20,424
ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
 CEO
 WEBSITEwww.artelobio.com
 EMPLOYEES5

Artelo Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Artelo Biosciences Inc? What does ARTL stand for in stocks?

ARTL is the stock ticker symbol of Artelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artelo Biosciences Inc (ARTL)?

As of Thu Feb 29 2024, market cap of Artelo Biosciences Inc is 4.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers. The fair value of Artelo Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artelo Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artelo Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ARTL is over valued or under valued. Whether Artelo Biosciences Inc is cheap or expensive depends on the assumptions which impact Artelo Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARTL.

What is Artelo Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ARTL's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 4.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARTL PE ratio will change depending on the future growth rate expectations of investors.